Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Amino Acids, Peptides, and Proteins (1)
- Animals (1)
- Bacteria (1)
- Bacterial Infections and Mycoses (1)
- Biochemistry (1)
-
- Biochemistry, Biophysics, and Structural Biology (1)
- Biophysics (1)
- Chemistry (1)
- Disease Modeling (1)
- Infectious Disease (1)
- Inorganic Chemicals (1)
- Life Sciences (1)
- Medical Specialties (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Medicinal and Pharmaceutical Chemistry (1)
- Medicinal-Pharmaceutical Chemistry (1)
- Musculoskeletal Diseases (1)
- Nucleic Acids, Nucleotides, and Nucleosides (1)
- Organic Chemistry (1)
- Other Chemicals and Drugs (1)
- Pharmaceutics and Drug Design (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
Articles 1 - 2 of 2
Full-Text Articles in Polycyclic Compounds
Design, Synthesis, And Nmr-Guided Characterization Of A Targeted Covalent Inhibitor-Like Molecule Against Ivyp1 From P. Aeruginosa, Samuel Taylor Moore
Design, Synthesis, And Nmr-Guided Characterization Of A Targeted Covalent Inhibitor-Like Molecule Against Ivyp1 From P. Aeruginosa, Samuel Taylor Moore
Master's Theses
Multi-drug resistance poses a serious threat to future generations and historical antibiotic pipelines; consequently, the medical and economic burdens associated with treating multidrug-resistant bacteria are substantiated. In this context, P. aeruginosa (PA) emerges as one of the most significant healthcare challenges, being a leading cause of resistance-associated mortality worldwide. Despite modern efforts to combat these poor outcomes, drug-resistant cases continue to rise, and the need for novel antibiotic treatment is apparent. To this end, we investigated relevant resistance mechanisms and past antibiotic targets within PA, and in doing so, we identified relationships between peptidoglycan biology and a periplasmic protein, Inhibitor …
Advancing Small Molecule Therapies For Myotonic Dystrophy Type 1, Sawyer M. Hicks
Advancing Small Molecule Therapies For Myotonic Dystrophy Type 1, Sawyer M. Hicks
Electronic Theses & Dissertations (2024 - present)
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by the expression of expanded CUG (CUGexp) repeat RNA from the myotonic dystrophy protein kinase (DMPK) gene. This CUGexp repeat RNA’s gain-of-function mechanism leads to the sequestration of muscleblind-like (MBNL) proteins, resulting in widespread alternative splicing dysregulation across tissues. Despite significant research, there are currently no approved therapeutics targeting the underlying causes of DM1. This dissertation explores the development and optimization of a novel class of small molecules, Modified Polycyclic Compounds (MPCs), designed to address splicing dysregulation in DM1. MPCs were designed from previously published …